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Abstract
Understanding the antibody response to HIV-1 in humans that show broad neutralizing serologic activity is a crucial
step in trying to reproduce such responses by vaccination. Investigating antibodies with cross clade reactivity is
particularly important as these antibodies may target conserved epitopes on the HIV envelope gp160 protein. To this
end we have used a clade B YU-2 gp140 trimeric antigen and single-cell antibody cloning methods to obtain 189 new
anti-gp140 antibodies representing 51 independent B cell clones from the IgG memory B cells of 3 patients infected
with HIV-1 clade A or B viruses and exhibiting broad neutralizing serologic activity. Our results support previous
findings showing a diverse antibody response to HIV gp140 envelope protein, characterized by differentially expanded
B-cell clones producing highly hypermutated antibodies with heterogenous gp140-specificity and neutralizing activity.
In addition to their high-affinity binding to the HIV spike, the vast majority of the new anti-gp140 antibodies are also
polyreactive. Although none of the new antibodies are as broad or potent as VRC01 or PG9, two clonally-related
antibodies isolated from a clade A HIV-1 infected donor, directed against the gp120 variable loop 3, rank in the top 5%
of the neutralizers identified in our large collection of 185 unique gp140-specific antibodies in terms of breadth and
potency.
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Introduction
A significant fraction of the patients infected with HIV-1
develop broadly neutralizing serologic activity 2–3 years after
infection [1,2,3,4,5,6,7,8]. Although these antibodies do not
protect infected patients, they put selection pressure on the virus
[9]. Additionally, and more importantly, passive transfer of
broadly neutralizing antibodies to monkeys effectively protects
them against SHIV infection [10,11,12,13,14,15,16,17,18,19].
Therefore, it has been proposed that vaccines that elicit such
antibodies may be protective against infection in humans
[20,21,22,23,24].
Despite a wealth of serologic information and significant efforts
to obtain representative broadly neutralizing antibodies, there
have been few systematic molecular studies of the anti-HIV-1
antibody response [25,26]. Nevertheless, several broadly neutral-
izing antibodies (bNAbs) to HIV-1 gp140 have been isolated
including a group that binds to gp120 (b12, 2G12, PG9/PG16,
HJ16 and VRC01) [26,27,28,29,30] and a group that is specific
for gp41 (2F5, 4E10 and Z13) [31,32,33]. The precise way in
which these unique and potentially important antibodies relate to
the serologic responses remains unclear. The serologic response to
HIV-1 is polyclonal and targets both internal and viral surface
proteins, but only antibodies directed against the HIV envelope
spike, gp160, mediate viral neutralization [24].
In order to examine the memory B cell compartment of HIV-1
infected patients we developed a method to directly clone
antibodies from anti-gp140 specific B cells [25,34,35]. Initially,
six elite controllers and slow progressors infected with HIV-1 clade
B were examined [25]. We found that the IgG memory antibody
response to the gp140 HIV envelope protein in those patients was
composed of differentially expanded clones (22 to 50 per patient)
that target a number of different gp120- and gp41-epitopes
[25,36], including a new epitope, ‘‘CD4bs/DMR’’ which is closely
apposed to the CD4 binding site (CD4bs), conserved between virus
variants and required for optimal HIV infectivity [37]. Although
no single monoclonal antibody mirrored the broad neutralizing
activity in serum, high concentrations of pools of antibodies from 2
of the 4 patients tested reconstituted the initial serologic
neutralizing activity [25]. Significantly, in addition to their specific
high affinity binding to HIV gp140, 75% of the 134 antibodies
were also polyreactive [38]. We have proposed that this property
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24078Figure 1. Production of anti-gp140 HIV antibodies from single memory B cells. A. Neutralization activity of purified IgGs from HIV-infected
patients (pt9-11) sera measured by TZM-bl assay. The y-axis shows the IgG concentration required to achieve IC50 for each viruses indicated on the x-
axis: 1, MW965.26, 2, DJ263.8; 3, SF162.LS; 4, SS1196.1; 5, BaL26; 6, 6535,3; 7, RHPA4259.7; 8, SC422661.8; 9, TRO.11; 10, PVO.4 for pt9 and pt10, and
CAAN5342.A2 for pt11; 11, YU2.DG. B. IgG antibody reactivity of pt9-11 patient sera against YU-2 trimeric gp140 and gp120 proteins determined by
ELISA. The grey area indicates the reactivity range of the serum IgGs from previously studied clade B HIV-infected patients (pt1 to pt6) [25] used as
comparison. C. Flow cytometry plots show the staining of patient PBMC with gp140 protein, anti-CD19 and anti-IgG antibodies. Gp140-rective IgG
memory B cells were identified as gp140+IgG+CD19+ cells in the lymphocyte gate. The pie charts below the flow cytometry plots show for each
patient the expansions of gp140-specific B-cell clones. The total number of memory B-cell antibodies is indicated in the center, each pie slice
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bivalent heteroligation of one high-affinity anti-gp140 combining
site and a second low-affinity polyreactive ligand [38].
Here, we extended our study of the human memory B-cell
response to HIV by characterizing 189 new anti-gp140 specific
antibodies representing 51 independent clones isolated from two
HIV-1 clade A and one clade B infected donors with broad
neutralizing serologic activity, none of which is an elite controller.
The antibody response to gp140 in these patients is highly
polyreactive and targets a diverse group of HIV-1 epitopes
including ‘‘CD4bs/DMR.’’ Although each individual antibody
neutralizes only a limited number of viral strains, many show
neutralizing activity to different tier 1 viruses and a limited
number of tier 2 viruses.
Results
Anti-gp140 antibodies from HIV-1 patients infected with
clade A and B viruses
Three HIV-1 infected donors with heterogenous levels of high
serologic neutralizing activity were studied (Figures 1A, Table S1).
Two were African donors infected with clade A HIV viruses (pt9
and pt10) and the other, a Caucasian donor, with a clade B virus
(pt11). Purified serum IgG from these patients showed similar
levels of ELISA binding activity to artificially trimerized YU-2
gp140 (gp140) and YU-2 gp120 as previously studied elite
controller HIV patients (Figure 1B) [25]. Consistent with the
ELISA results, we found that 0.37–0.54% of the peripheral IgG
+ B
cells from the three patients bound YU-2 gp140 as measured by
flow cytometry [35] (Figure 1C). Despite relatively high titers of
neutralizing antibodies, one of the patients, pt11, showed a
dramatic reduction in the overall frequency of IgG
+ B cells in a
manner consistent with memory compartment exhaustion
(Figure 1C) [39].
Immunoglobulin heavy and light chains were cloned from
cDNA libraries prepared from single gp140-specific memory B
cells isolated by flow cytometry [35,40]. Of the 189 antibodies
obtained, 182 were members of 44 variably expanded clonal
families (Figure 1C and Table S2). Since nearly all of the gp140-
binding B cells in clade B HIV-infected donors were members of
expanded clones of B cells [25], we selected representative
members of each clonal family for expression and further analysis
(Table S2).
All 51 of the selected antibodies bound to YU-2 gp140 as
measuredbyELISA(Figure1D).Moreover,analysisoftheantibody
affinity by surface plasmon resonance showed that antibodies
isolated from clade A HIV patients bound with high affinity to clade
B YU-2 gp140 and gp120 ligands (Figures 1E and S1). The
apparent affinity constants (KA
app) of the antibodies varied between
4.9610
27 to 7.3610
211 for gp140 and 1.5610
27 to 9.4610
210
gp120 (Figure S1C). Thus the KA
app of the antibodies from clade A
infected patients were comparable to the values obtained from clade
B infected individuals [25] (Figure 1F).
Immunoglobulin gene repertoire
Features of the antibodies produced from clade A (pt9 and pt10)
and clade B (pt11) infected patients were analyzed individually and
as a group (Table S2). Similar to the clade B elite controllers, the
antibodies from the new patients were highly biased towards VH1
usage, and enriched for longer, charged IgH complementary-
determining region 3 (CDR3) (Figure 2A). In addition, the heavy-
and light-chain variable region genes (VH and Vk, respectively)
from anti-gp140-reactive antibodies were highly mutated when
compared to non gp140-reactive antibodies isolated from clade B
infected elite controllers [25] or historical controls [25,41]. Indeed,
the average number of VH and Vk mutations in pt9-11 patients
was significantly higher than in previously studied pt1-6 patients
[25] (35.2 vs 26.8 for VH, p,0.0001 and 18.1 vs 11.7 for Vk,
p,0.0001) (Figure 2C). Moreover, as observed for the initial group
we found a bias to Igk light chain usage (Figure 2B). We conclude
that the Ig repertoire of anti-gp140 antibodies found in clade A
and B HIV-1 infected patients is similar to that described for elite
controllers and slow progressors.
gp140-epitopes targeted by IgG memory antibodies
To determine whether the anti-gp140 antibodies bound to
gp120 or gp41 we performed ELISA experiments with purified
proteins. We found that the majority of the antibodies were
specific for gp120 protein (75% vs 25% for gp41-reactivity)
(Figure 3A). None of the anti-gp41 antibodies (n=13) were
directed against the membrane proximal peptides recognized by
2F5 and 4E10 bNAbs [31,33], and only 31% of the anti-gp41
antibodies showed binding to the immunodominant region of
gp41 [36,42] (Figure 3B).
To further map the fine specificity of the anti-gp120 antibodies
we performed ELISAs using mutant proteins: gp120(D368R)
interferes with the binding of antibodies to the CD4 binding site
(CD4bs) [6]; gp120(I420R) interferes with the binding of antibodies
to the CD4 induced co-receptor binding site (CD4i) [43]; gp120
core
protein lacksvariableloops(VL)whichinterfereswith the bindingof
anti-VL and anti-CD4i antibodies [44]. Thus, antibodies that bind
to gp120, gp120(D368R) and gp120(I420R) but not to gp120
core
were classified as anti-VL antibodies and those that bind to gp120
and gp120(D368R) but not to gp120(I420R) and gp120
core were
classifiedasanti-CD4iantibodies.Anti-CD4bsantibodiesonlyshow
inhibitionof bindingto gp120(D368R). Finally, antibodies that bind
to gp120, gp120(D368R), gp120(I420R) and gp120
core were
classified as anti-gp120
core antibodies. Among these, antibodies
that show inhibition of binding to D474A/M475A/R476A gp140
mutantprotein(gp140(DMR/AAA))wereclassifiedas anti-CD4bs/
DMR antibodies [37].
Similar to the previously characterized elite controller group
[25], the anti-gp120 antibodies cloned from pt9-11 targeted all
known gp120 epitopes with variable relative representation in all
three patients (Figure 3C and Table S2). However, in contrast to
the elite controllers and slow progressors, only two of the five
antibodies to the gp120
core epitope were sensitive to the D474A/
represents a clonal family and the area of the slice is proportional to the number of clonal relatives. Each clonal family is represented by the same
color and unique antibodies that are not members of a clonal family are not colored. D. Gp140-antibody binding by ELISA of anti-gp140 monoclonal
antibodies isolated from gp140+IgG+CD19+ cells in HIV-infected patients. The red and black dotted lines show positive (b12) [27] and negative
(mGO53) [34] antibody controls. All the experiments were performed at least in duplicate. Representative data are shown. The pie chart indicates the
numbers of gp140-reactive antibodies produced from each HIV+ donor with the total number in the center. E. Antibody binding to gp140 and gp120
measured by surface _lasmon resonance (SPR). The SPR sensorgrams for antibody binding to gp140 and gp120 overtime are shown for 10-939 and
10-923 as example. The antibodies were tested at concentrations ranging from 2.5 nM (black curve) to 40 nM (orange curve). RU, response units. F.
Apparent affinities (KA
app) to gp140 and gp120 ligands determined by SPR (as shown in E) for the anti-gp140 antibodies isolated from clade A HIV-
infected African patients (filled circles) in comparison to the previously studied gp140-reactive antibodies produced from clade B HIV+ donors (open
circles) [25]. Student t-test shows no statistical difference.
doi:10.1371/journal.pone.0024078.g001
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junction of gp120, which is essential for optimal viral infectivity
[37] (Figures 3D and S2). Although this is a small number of
‘‘core’’ antibodies, the results suggest the existence of additional
epitopes that differ from those recognized by conventional anti-
CD4bs and anti-CD4bs/DMR antibodies.
Heterogeneous neutralizing activity
To determine the in vitro neutralizing activity of the fifty-one
anti-gp140 IgG memory antibodies, we measured their capacity to
inhibit TZM-bl cell infection by pseudovirus variants [45]. Most of
the anti-gp120 antibodies (66%, n=38) exhibited measurable
levels of neutralization activity against our panel of 11 pseudo-
viruses (Figure 4). In contrast, only 2 of the 13 anti-gp41 antibodies
(10-437 and 11-788) showed any activity and in both cases only
against the same tier-1 virus (MW965.26, Figure 4). When
segregated according to their gp120 epitope specificity the anti-
CD4bs showed the highest frequency of antibody neutralizers
followed in order by gp120
core, CD4i and VL reactive antibodies
(Figure 5A). However, the average number of viruses neutralized
and the mean IgG concentration required to reach the IC50 for
neutralization was similar for the different gp120-targeted epitopes
(Figure 5B and C).
To determine whether the anti-gp140 antibodies isolated from
clade A HIV-infected donors (pt9 and pt10) using clade B YU-2
gp140 bait might display increased neutralization breadth, we
measured the neutralizing activity of most of the antibodies from
pt9-pt10 patients (n=19) against a broader panel of 22 additional
HIV pseudo-viruses (Table S3). Of the anti-gp120 antibodies that
showed neutralizing activity in both virus panels (n=9, 33 viruses
tested in total), tier 1 viruses were most frequently neutralized
(67615% vs 966% for tier-2 viruses) (Table 1). However, there
was no tendency toward preferential neutralization of clade A, B
or C viruses by the antibodies derived from clade A HIV patients
(Table 1). Significantly, anti-VL 10-188 antibody isolated from the
same patient (pt10) was the only one to show activity against the
resistant tier-2 YU-2 virus, from which the bait was derived
(Figure 4). This antibody ranked in the top 5% of the neutralizers
identified in our collection of 185 unique anti-gp140 antibodies 99
of which show some neutralizing activity [25]. We conclude that
neutralizing activity of the antibodies derived from clade A
infected patients with the clade B YU-2 gp140 trimer are similar in
neutralizing activity to those isolated from clade B infected elite
controllers and slow progressors [25].
Neutralizing antibody 10-188 binds to the V3 crown
10-188 was a member of an expanded clonal family containing
four other antibody variants characterized by intra-clonal
diversity, specifically in the length of their IgH CDR3 regions
(Figures 6A and 6B, and Table S2). To determine whether such
structural variation could have an influence on neutralization, we
assayed the neutralization of 10-380, the most distal clonally
related variant of 10-188 (Figures 6A and 6B, and Table S2). 10-
380 showed neutralizing potency and breadth comparable to 10-
188 when tested for the same virus panels (Figure 4, Tables 1 and
S3). To better characterize the epitope recognized by 10-188 and
10-380, we examined their reactivity by ELISA using a library of
overlapping 20-mer peptides covering the entire YU-2 gp120
sequence (Figure 6C and Table S4). The epitope targeted by 10-
188 and 10-380 was mapped into the crown of the gp120 variable
loop 3 (V3), and was composed of the minimal peptide
NIGPGGRALYTT (Figures 6C and 6D). Taken together, the
results indicate that there is a consensus antibody sequence shared
by the different members of the 10-188 clonal family allowing their
binding to the V3 crown and potent neutralization.
Polyreactivity of gp140-specific B cell antibodies
Seventy five percent of the anti-gp140 memory antibodies
cloned from the elite controller group are polyreactive (pt1-6,
[38]). To determine whether the anti-HIV antibodies cloned from
pt9-11 patients are also polyreactive, we measured their binding to
ssDNA, dsDNA, LPS, and insulin by ELISA (Figure 7A).
Although there was no increase in serologic polyreactivity between
the three HIV patients and healthy controls (Figure S3), 69% of all
of the pt9-11 anti-gp140 memory antibodies were polyreactive
(Figure 7B, p,0.0001 compared to uninfected controls and
antibodies that did not bind to gp140 antibodies from pt2-3
patients [25,41]). The frequency of polyreactive antibodies varied
between patients (from 57 to 83%): however, as a group, pt9-11-
antibodies were indistinguishable from those obtained from pt1-6
[25](69% vs 75%, p=0.46). In addition, pt9-11 anti-gp41
antibodies were slightly more polyreactive than anti-gp120
(Figure 7C, [38]). We conclude that increased levels of
polyreactivity are found in anti-HIV gp140 antibodies derived
from clade A and B infected patients.
Discussion
We have characterized fifty one new human gp140-specific
antibodies cloned from YU2 gp140 trimer-binding IgG memory B
cells from clade A and B HIV-infected patients with broad
neutralizing serologic activity. Our findings extend previous work
on anti-gp140 antibodies isolated from elite controllers infected
with clade B HIV-1. Notably the pt9-11 antibodies show (i) an IgG
gene repertoire that is enriched for VH1 and Igk light chain genes,
as well as long and charged IgH-CDR3s; (ii) the new memory
antibodies bind with high affinities to a number of different
epitopes on both gp120 and gp41 proteins; (iii) the majority of the
anti-gp120 antibodies show neutralizing activity against tier-1
viruses, while neutralization by anti-gp41 antibodies was rare; (iv)
finally, the majority of the anti-gp140 antibodies were polyreactive
[25,38].
Using a clade B gp140 protein as ‘‘bait’’ to isolate memory B
cells from clade A HIV patients might be expected to select for
cross-reactive B-cell clones with broad neutralizing capacities.
Surprisingly, the anti-gp140 antibodies isolated from the clade A
Figure 2. Ig gene repertoire of gp140-specific IgG memory B-cell antibodies. The IgH and IgL chain gene features of anti-gp140 memory B
cell antibodies isolated from clade A (pt9 and pt10 shown as a group) and B (pt11) HIV+ patients are shown in comparison to previously published
anti-gp140 (pt1-6 gp140+) and non-gp140 reactive (pt2-3 gp140-) antibodies [25] and control antibodies from IgG memory B cells from healthy
donors (HC-IgGm) [41]. A. IgH V and J gene usages, CDR3 length and CDR3 positive charge numbers from gp140-specific memory B cell antibodies in
clade A and B HIV-infected patients compared to controls. The number of antibody sequences analyzed is indicated in the center of each pie chart.
The average of IgH CDR3 length is indicated above each histogram. P-values indicated below the pie charts or histograms and the lines were
calculated by comparison to the HC-IgGm and anti-gp140 (pt1-6 gp140+) control antibodies, respectively [25,41]. B. IgL k/l usage, V and J gene
usages for Igk in gp140-specific memory B cell and control antibodies as shown in A. C. The numbers of mutations in VH and Vk genes in gp140-
specific memory B cell and control antibodies as shown in A. The average number of mutations in VH and Vk genes is indicated below each dot plot.
The p-values were determined by comparison to HC-IgGm and anti-gp140 (pt1-6 gp140+) control antibodies [25,41] using unpaired student’s t-test.
doi:10.1371/journal.pone.0024078.g002
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from the clade B patient pt11 or from the previously studied clade
B-infected donors in nearly all respects [25]. How this might
change if we were to use clade A envelope proteins remains to be
determined. In addition, none of the individual antibodies isolated
had bNAb properties. This raises the question of a potential lack of
efficiency of our single-cell capture method using the soluble
recombinant YU-2 gp140 trimer to isolate broadly neutralizing B
cells/antibodies. In contrast to our results, an extremely potent
and broad antibody, VRC01, was obtained using an artificially
resurfaced protein as bait suggesting that the YU-2 gp140 trimer
bait is limiting for antibody capture [30]. However, the two
experiments were done with independently collected samples and
other factors that might influence the efficiency of cloning such as
the primer set and its susceptibility to hypermutation of anti-HIV
antibodies were not explored.
It is important to note that two anti-V3 clonally-related
antibodies with potent neutralizing activities isolated from clade
A HIV pt10 patient, ranked in the top 5% of the antibody
neutralizers in our collection of 185 anti-gp140 antibodies. The
neutralization spectra of those two antibodies were indeed
comparable to the ones described for other V3-specific antibodies
that mostly neutralize tier 1-viruses and only 10–25% of tier 2-
viruses [26,46,47].
Two groups have identified bNAbs from non-clade B HIV-1
infected individuals by EBV-mediated B-cell immortalization
and large-scale neutralization screening [26,29]. Corti et al.
isolated anti-core-DMR antibody HJ16 from a clade C-infected
patient [26], and Walker et al. identified anti-VL1/2 antibodies
PG9 and PG16 from pt9 [29]. Furthermore, Walker et al.
recently showed that most of the serum neutralizing activity
from pt9 could not be immunoadsorbed with the artificial YU-2
gp140 trimer used in our experiments [48]. This may explain
why (i) serum IgGs isolated from pt9 only neutralized YU-2 at
very high concentrations (.0.5 mg/ml) and showed a weaker
binding reactivity to YU-2 gp140 by ELISA compared to the
other serum IgGs; (ii) the relatively low number of gp140-
binding cells detected by flow cytometry using the YU-2 gp140
protein ’’bait’’, (iii) the relatively small number of anti-gp140
antibodies cloned from this donor [29]. Thus, the YU-2 gp140
trimer would not be an appropriate bait to try to capture specific
broadly neutralizing antibodies from patients like the one that
produced PG9/16.
Two conserved features of anti-HIV-1 memory antibodies
stand out: high rates of hypermutation and polyreactivity [25,38].
We first noted abnormally high levels of somatic hypermutation
in anti-HIV-1 antibodies in elite controllers [25]. Reversion of 20
randomly selected antibodies to the germline showed that
hypermutation is essential for viral neutralizing activity and
breadth [38]. Similarly, reversion of the hypermutations in the
recently reported bNAb VRC01 eliminates its neutralizing
activity [49]. The fact that high levels of hypermutation were
found in antibodies cloned from pt9-11 indicates that this is an
important conserved feature of the human anti-HIV-1 antibody
response.
Anti-HIV antibody polyreactivity was first noted in an anti-p24
antibody [50]. Haynes et al. and others then showed that two anti-
gp41 bNAbs, 2F5 and 4E10, were polyspecific and reactive against
membrane phospholipid, i.e., cardiolipin [51,52,53]. We recently
found that this is a more general feature of the human anti-HIV-1
response in clade B infected elite controllers where 75% of the 134
unique anti-gp140 antibodies tested were polyreactive. The
present study confirms and extends these findings to clade-A
patients, who are not elite controllers. Remarkably, this atypical
property of anti-HIV-1 antibodies increases their binding affinity
to HIV-1 by allowing a bivalent heteroligation between one high-
affinity anti-gp140 combining site and a second low-affinity site on
a yet-to-be-defined HIV-1 virus surface component [38]. En-
hanced antibody binding by polyreactive heteroligation is
reminiscent of the finding that 2F5 and 4E10 bind to epitopes in
the membrane proximal region of gp41 but also interact with
lipids on the virion membrane [52,54,55,56]. Moreover, Diskin
et al. recently demonstrated that the anti-CD4i 21c antibody
interacts simultaneously with CD4i and CD4 [57]. It has been
proposed that heteroligation is positively selected because the
number of viral spikes on HIV-1 is too small to allow for bivalent
homotypic antibody binding. Although we have not explored the
ability of the antibodies described here to mediate heteroligation
or to interact with two different parts of the HIV spike as suggested
by Diskin et al., conservation of polyreactivity among antibodies
from patients infected with different HIV-1 clades further supports
the idea that heteroligation may be an important feature of the
human anti-HIV-1 antibody response.
Materials and Methods
Patients
The study was performed in accordance with and after ethic
approval from the Institutional Review Board of the Rockefeller
University and of the International AIDS Vaccine Initiative, IAVI
(Protocol G) [7]. All patients gave written consent to participate in
this study. Peripheral blood mononuclear cells (PBMC) and sera
were collected from a cohort of HIV-1 infected individuals (IAVI
Protocol G) as previously described [7].
Figure 3. Epitope mapping of anti-gp140 antibodies. A. ELISA binding analyses of anti-gp140 antibodies against gp120 and gp41 proteins.
Red dotted lines represent the positive antibody controls b12 and 4e10 for gp120 and gp41, respectively [27,32]. The pie charts show the distribution
of gp120 (green slice) and gp41 (blue slice) reactive antibodies among anti-gp140 antibodies isolated from clade A and B HIV-infected patients.
Gp120/gp41 reactivities of previously published anti-gp140 antibodies (from pt1 to pt6 HIV patients) are shown for comparison [25]. The total
number of tested antibodies is indicated in the center of each pie chart. 262 Fisher’ exact test shows no statistical difference. B. ELISA testing of anti-
gp41 antibody binding to MPER-peptides (including 4e10- and 2F5-epitopes) and immunodominant (ID) peptide (9 gp41-reactive antibodies tested).
ELISA binding curves of positive antibody controls (4e10, 2F5 and 2-378 [25,31,32]) are shown in each graph as red dotted lines. C. Antibody binding
to gp140, gp120, gp41, gp120
core, gp120(D368R) and gp120(I420R) proteins measured by ELISA for representative antibodies directed against the
CD4 binding site (CD4bs), the CD4 induced site (CD4i), the variable loops (VL) and the core of gp120 (gp120
core). The distribution of the antibody
reactivities to the gp41, CD4bs, CD4i, VL and gp120
core according to the clonally related B-cell expansions is depicted for each HIV patient as pie
charts. The total number of memory B-cell antibodies is indicated in the center, each pie slice represents a clonal family and the area of the slice is
proportional to the number of clonal relatives. Each clonal family is represented by the same color and unique antibodies that are not members of a
clonal family are not colored. D. Antibody binding to BaL gp140 and gp140(DMR/AAA) mutant protein [37] by ELISA for the representative anti-
gp120
core antibodies. 10-390 and 10-743 are DMR/AAA-mutation non-sensitive and sensitive, respectively. The bar diagram on the right-hand side
shows the relative binding of the anti-gp120
core and control antibodies [37] to the gp140(DMR/AAA) mutant compared to the gp140 protein. Error
bars indicate the SEM. The orange bars show antibodies sensitive to DMR/AAA-mutation. The cutoff is shown by the dotted line. All the experiments
were performed at least in duplicate. Representative data are shown.
doi:10.1371/journal.pone.0024078.g003
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All human anti-gp140 monoclonal antibodies used as controls in
this study were previously characterized [25,27,28,31,32,37], and
expressed by cotransfection of HEK 293T cells as described below.
Protein production and purification
Expressing vectors encoding for YU-2 gp120 (obtained from J.
Sodroski), gp120 (D368R) and gp120 (I420R) mutant proteins
(obtained from J. R. Mascola and R. T. Wyatt, [6,43]), BaL gp140
protein and BaL gp140 (D474A/M475A/R476A) mutant [37]
were used to transfect HEK 293T cells as described below. After
harvesting of culture supernatants, proteins were purified by
successive lectin and nickel-chelating affinity chromatographies
[37]. Purified YU-2 gp120
core protein [44] was kindly provided by
J. R. Mascola and R. T. Wyatt. Gp41 (ectodomain amino acids
541 to 682; strain HxB2) was purchased at Acris, Herford.
gp140-specific B cell sorting
Peripheral B cells were isolated from patient PBMC by
magnetic B cell enrichment using human CD20 microbeads or a
B cell enrichment kit (Miltenyi). Single gp140+CD19+IgG+ B cells
were identified by staining with biotinylated gp140 [35]/
Streptavidin-PE (Caltag), anti-CD19-FITC and anti-IgG-APC
(BD Biosciences Pharmingen) and sorted into 96-well PCR plates
using a FACSVantage sorter (Becton Dickinson) as previously
described [34,35].
RT-PCR and expression-vector cloning
Single-cell cDNA synthesis using SuperScript III reverse
transcriptase (Invitrogen) followed by nested-PCR amplifications
of IgH, Igk and Igl genes were performed as previously described
[40]. All PCR products were sequenced and analyzed for Ig gene
usage, CDR3 analyses and number of VH/Vk somatic hypermu-
Figure 4. Neutralizing activity of anti-gp140 antibodies in TZM-bl assay. Numbers indicate antibody IgG concentrations in mg/ml to reach
the IC50 in the in vitro TZM-bl neutralization assay. . indicates that the IC50 for a given virus was not reached at the concentration tested. 9-1487
antibody was not tested for viral neutralization. *10-188 and 10-380 are clonally related antibodies. ND, not determined. MuLV, Murine leukemia virus,
is the negative control.
doi:10.1371/journal.pone.0024078.g004
Figure 5. Neutralizing potency and breadth of anti-gp140 antibodies. A. The neutralizing activity measured by TZM-bl assay is shown for
individual antibodies according to their epitopes (targeted regions of gp120) are shown in the graphs. The y-axis shows the IgG antibody
concentration required to achieve IC50 for each viruses indicated on the x-axis: 1, DJ263.8; 2, SF162.LS; 3, BaL26; 4, SS1196.26; 5, MW965.26; 6, 6535,3;
7, YU2.DG. The pie chart above each graph indicates the frequency of antibody neutralizers in each epitope group, with the total number of
antibodies tested in the center. B. Antibody neutralizing potency and breadth according to the targeted gp120-epitopes. The bubble plot shows for
the antibody neutralizers (with neutralization of at least 2 viruses) grouped by gp120-targetted epitopes (x-axis), the mean IgG antibody
concentration required to achieve IC50 (y-axis) and the average number of viruses neutralized (indicated by the bubble size and by the number in the
center of the bubble). C. The distribution of the antibody neutralizers (with neutralization of at least 1 virus) binding to the gp140 epitopes according
to the clonally related B-cell expansions is depicted for each HIV patient as pie charts. The total number of neutralizing antibodies is indicated in the
center, each pie slice represents a clonal family and the area of the slice is proportional to the number of clonal relatives. Each clonal family is
represented by the same color and unique antibodies that are not members of a clonal family are not colored. The star indicates that only one virus
out 11 was neutralized by the 2 anti-gp41 antibodies.
doi:10.1371/journal.pone.0024078.g005
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IMGTH; http://www.imgt.org). Control data from previously
published anti-gp140 and non gp140-reactive antibodies isolated
from 6 clade B HIV-infected patients [25], and antibodies isolated
from the IgG+ memory B cells of three healthy donors were used
as comparison [41]. Purified digested PCR products were cloned
into human Igc1-, Igk-o rI g l-expressing vectors as previously
described [40]. Vectors containing IgH and IgL genes were
isolated from transformed-DH10b bacteria using plasmid DNA
purification kits (NucleoSpinHPlasmid, Macherey-Nagel; or Pure-
Link
TM plasmid maxiprep kit, Invitrogen), then sequenced and
compared to the original PCR-product sequences. The memory
phenotype of the isolated gp140-specific B cells was confirmed by
the presence of gene features associated with post-germinal center
cells [58,59].
Antibody production and purification
Antibodies were produced by transient co-transfection of
exponentially growing HEK 293T cells (ATCC, CRL-11268)
using polyethylenimine (PEI)-precipitation method. Briefly, 293T
cells growing in DMEM (GibcoH Invitrogen) supplemented with
10% FBS (HyClone, Thermoscientific), and 1 mM sodium
pyruvate (GibcoH Invitrogen), antibotics/antimycotics (GibcoH
Invitrogen) were washed at 80% cell-confluency using serum-free
Figure 6. Sequence analyses and epitope mapping of 10-188 antibody. A. IgH amino acid alignment of 10-188 with its germline precursor
and clonal relatives. Red shading shows amino acid identity, yellow shows biochemical similarity. The consensus sequence is shown above, dashes in
this sequence indicate non-conserved residues CDR, complementary determining regions; FR, framework regions. B. Phylogenetic tree of the 10-188
clonal family generated from the IgH sequence alignment shown in A. C. ELISA graph shows the epitope mapping for 10-188 and 10-380 antibodies
using as antigens, overlapping 20-mer peptides covering the entire YU-2 gp120 sequence. The amino acid sequence of each numbered peptide is
indicated in Table S4. Sequences of the reactive V3 peptides are indicated on top of the curves. D. Graph shows the ELISA measuring the reactivity of
10-188 and 10-380 antibodies against the V3-peptide NNNTRSINIGPGGRALYTT. Green and red lines show the negative (mGO53, [34]) and positive (1–
79, [25]) controls, respectively. All the experiments were performed at least in duplicate. Error bars indicate the SEM. Approximate KD values
calculated from the ELISA binding curves are indicated.
doi:10.1371/journal.pone.0024078.g006
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DMEM supplemented with 1% Nutridoma-SP (Roche), 1 mM
sodium pyruvate (GibcoH Invitrogen), and antibotics/antimycotics
(GibcoH Invitrogen). Equal amounts of Ig-H and IgL-expressing
vectors (15 mg of each plasmid DNA per plate) were mixed in
1.2 ml of 150 mM NaCl. After adding 200 ml of 0.45 mg/ml PEI
(Sigma) and vortexing for 20 s, the mixture was incubated for
10 min at room temperature to allow formation of precipitates and
gently distributed to the culture plate. Cells were cultivated 4 days
at 37uC in a 5% CO2 air atmosphere before harvesting of the
supernatants. IgG antibodies were affinity purified using Protein G
sepharose beads (GE Healthcare) according to the manufacturer’s
instructions and their concentration determined by IgG-ELISA as
previously described [34].
ELISAs
The antibody binding to YU-2 gp140 protein was tested by
ELISA as previously described [25]. Briefly, high-binding 96-well
ELISA plates (Costar) were coated overnight with 100 ng/well of
purified gp140 in PBS. After washings, plates were blocked 2 h
with 2% BSA, 1 mM EDTA, 0.05% Tween-PBS (Blocking buffer).
gp140-coated plates were incubated 2 h with IgG antibodies
diluted at 4 mg/ml and three consecutive 1:4 dilutions in PBS.
After washings, the plates were revealed by incubation for 1 h with
goat HRP-conjugated anti-human IgG (Jackson ImmunoReseach)
(at 0.8 mg/ml in blocking buffer) and by adding 100 ml of HRP
chromogenic substrate (ABTS solution, Invitrogen) after washing
steps. Optical densities were measured at 405 nm (OD405 nm)
using an ELISA microplate reader (Molecular Devices). Back-
ground values given by incubation of PBS alone in coated wells
were subtracted. For epitope mapping analyses, the anti-gp140
antibodies were tested by ELISAs as described above using as
antigens, YU-2 gp120, gp41, gp120
core, gp120 D368R, and gp120
I420R proteins as antigens. To assay the antibody binding to gp41
peptides (Imunodominant region (ID), DQQLLGIWGCSGK-
LICTTTV; 2F5, SQNQQEKNEQELLALDKWAS; 4E10,
LWNWFDITKWLWYIKIFIMI; 2F5-4E10, ELLALDK-
WASLWNWFDITKW) [36] and to YU-2 gp120 overlapping
peptides (Table S4), the anti-gp140 IgG antibodies were tested
using a previously described peptide-ELISA method [60]. Analysis
of the antibody binding to BaL gp140 and gp140 (DMR/AAA)
mutant protein was performed using a previously described
capture-ELISA assay [37]. The relative binding of anti-gp120
core
antibodies to gp140 (DMR/AAA) mutant protein was calculated
with OD values within the linear range of the ELISA curves, using
the following formula: (OD
gp140 (DMR/AAA)/OD
gp140) x 100.
Antibodies and serum IgGs were tested for polyreactivity as
previously described [34,38] and considered polyreactive when
they recognized at least two structurally different antigens out of
the four tested; ssDNA, dsDNA, insulin, and LPS. Threshold
values for reactivity were determined by using control antibodies
mGO53 (negative), eiJB40 (low positive), and ED38 (high positive)
[34,61]. IgGs isolated from the serum of HIV, and SLE patients
and healthy humans [38] by Protein G affinity purification were
tested by polyreactivity-ELISA as described above. All ELISA
experiments were performed at least in duplicates.
Surface plasmon resonance
All experiments were performed with a Biacore T100 (Biacore,
Inc) in HBS-EP+ running buffer (Biacore, Inc) at 25uC. YU-2
gp140 and gp120 proteins at 125 mg/ml were immobilized on
CM5 chips (Biacore, Inc.) by amine coupling at pH 4.5 resulting
in an immobilization level of 10,000 RUs. For kinetic measure-
ments on the gp140- and gp120-derivatized chips, IgGs were
injected through flow cells at 40 nM and 4 successive 1:2-dilutions
in HBS-EP+ running buffer (Biacore, Inc.) at flow rates of 40 ml/
min with 3 min association and 5 min dissociation. The sensor
surface was regenerated between each experiment with a 30
second injection of 10 mM glycine-HCl pH 2.5 at a flow rate of
50 ml/min. Off rate (kd (s
21)), on rate (ka (M
21 s
21 and RU
21 s
21
for ka2)) and binding constants (KD (M) or KA (M
21 and RU
21 for
KA2)) were calculated after subtraction of backgrounds (binding to
control flow cells and signal of the HBS-EP+ running buffer) using
Biacore T100 Evaluation software using the kinetic analysis and
the bivalent binding model. The KA1 value was used as an
estimation of apparent KA (KA
app) as previously described [62].
The sensorgrams showed in Figures 1E and S1 are derived from
the Biacore data processing using Scrubber 2 sofware (Center for
Biomolecular Interaction Analysis, University of Utah).
Neutralization assays
Virus neutralization was measured using a luciferase-based
assay in TZM.bl cells as previously described [45]. Antibodies
were also tested for virus neutralization at Monogram Biosciences
[63].
Multiple sequence alignments
All multiple sequence alignments were conducted using
CLUSTALW2 with default parameters. Alignment shadings were
generated using TeXshade package. The consensus sequences for
multiple alignments were generated based on identity and
similarity between residues ($70%). The amino acids were
grouped based on biochemical similarity as: FYW, ILVM, RK,
DE, GA, ST and NQ. The relationship between sequences was
generated using the Neighbor-Joining method. The bootstrap
consensus tree inferred from 1,000 replicates was taken to
represent the relationship. The percentage of replicate trees in
which the associated sequence clustered together in the bootstrap
test (1,000 replicates) is shown next to the branches. The tree is
drawn to scale, with branch lengths in the same units as those of
the evolutionary distances used to infer the phylogenetic tree. The
evolutionary distances were computed using the number of
differences method and are in the units of the number of amino
Table 1. Neutralization breadth of the selected anti-gp120
antibodies isolated from clade A HIV-infected patients.
Tier Clade
12 A B C
9-201 83 15 20 31 33
9-383
# 67 0 ND ND ND
9-867 50 4 20 6 22
9-913 83 11 40 25 22
9-939 33 0 20 0 11
10-188* 100 19 20 50 22
10-346
# 67 18 ND ND ND
10-380* 83 15 20 44 11
10-390 67 4 20 19 11
10-415 50 7 40 6 22
The numbers correspond to the percentage of virus neutralized.
#not all the viruses were tested, see Table S3.
*10-188 and 10-380 are clonally related antibodies.
ND, not determined.
doi:10.1371/journal.pone.0024078.t001
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removed for each sequence pair. Evolutionary analyses were
conducted in MEGA5 (http://www.megasoftware.net).
Statistics
P values for Ig gene repertoire analyses, analysis of lengths,
positive charges, of IgH CDR3, and antibody reactivity were
calculated by 262o r2 65 Fisher’s Exact test. The numbers of VH
and Vk mutations were compared across groups of antibodies
using unpaired student t-test.
Supporting Information
Figure S1 Binding affinity of anti-gp120 antibodies
isolated from clade A HIV-infected patients. Surface
plasmon resonance (SPR) analyses of the interaction of the
selected anti-gp140/gp120 IgG antibodies with the gp140 (A) and
gp120 (B) ligands immobilized on the sensor chips. Graphs show
SPR sensorgrams over time for the binding of the selected
antibodies. RU; response units. The on-rate, off-rate and affinity
constant values for the antibody/ligand interactions shown in A
and B are given the table in C. *10-188 and 10-380 are clonally-
related antibodies. M, mol/; s, seconds. -, not determined.
(PDF)
Figure S2 Reactivity of anti-gp120core antibodies
against gp140 DMR/AAA mutant. ELISA binding curves
show the reactivity of anti-gp120
core antibodies against BaL gp140
and BaL gp140 DMR/AAA mutant [37]. Antibodies sensitive
(anti-gp120
core, 4-77 antibody) and non-sensitive (anti-VL 2-1092,
b12 and 2G12 antibodies) to DMR/AAA triple mutation were
used as controls [37]. Mean values from two independent
experiments are shown. Error bars indicate SEM.
(PDF)
Figure S3 Reactivity of serum IgG from HIV patients.
Serum IgG reactivity of HIV patients pt9 to pt11 (red lines) and
Figure 7. Polyreactivity of anti-gp140 IgG memory B-cell antibodies. A. Graphs show ELISAs measuring reactivity against dsDNA, ssDNA,
insulin and LPS for IgG antibodies cloned from gp140+ memory B cells from patient pt9, pt10 and pt11. Dotted lines represent the positive control
antibody ED38 [61]. Horizontal lines show cut-off OD405 nm for positive reactivity. Green and red lines show the negative control antibody mGO53 and
low positive control antibody eiJB40, respectively [34]. All the experiments were performed at least in duplicate. Representative data are shown. Pie
charts summarize the frequency of polyreactive (black) and non-polyreactive (white) gp140-reactive memory B cell clones. The number of tested
antibodies is indicated in the pie chart center. B. The dot plot shows the polyreactivity frequency of gp140-specific IgG memory B-cell antibodies
isolated from pt9-pt11 HIV-patients compared to anti-gp140 antibodies from previous studied patients (pt1 to pt6) [25] and control antibodies (non
gp140-binding antibodies from pt2-3 patients [25] and HC-IgGm antibodies [41]). Each symbol represents a donor. Groups were compared using 265
Fisher’s Exact test.
***,p ,0.001. C. Pie charts summarize polyreactivity of anti-gp140 antibodies grouped by antibody specificity for gp41 and gp120.
Reactive (black) and non-reactive (white) IgG antibodies, numbers in the center indicate number of antibodies tested. 262 Fisher’s Exact test shows
no statistical difference between both groups.
doi:10.1371/journal.pone.0024078.g007
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ssDNA, Insulin, and LPS used as antigens in the polyreactivity
ELISA [34,38]. The green line shows the reactivity of serum IgG
from one SLE patient used as positive control [64].
(PDF)
Table S1 Neutralizing activity of purified IgG from HIV
patient sera in TZM-bl assay. Numbers indicate serum IgG
concentrations in mg/ml to reach the IC50 in the TZM-bl
neutralization assay. . indicates that the IC50 for a given virus was
not reached at the concentration tested. ND, not determined.
(PDF)
Table S2 Repertoire and reactivity of gp140-specific
antibodies. *10-188 and 10-380 are clonally related antibodies.
(-) and (+) indicate the numbers of negatively and positively
charged amminoacids in the IgH complementary determining
region (CDR3), respectively. VHmut and Vk/lmut indicate the
total number of mutations in the VH and VL Ig genes. # exp.,
number of clonally related expansions; # rel., number of conally
related members. gp41-ID, gp41 immunodominant epitope; V3,
variable loop 3 of gp120. Neut., neutralization activity; Poly.,
polyreactivity.
(PDF)
Table S3 In vitro neutralization assay of the anti-HIV
gp140 antibodies isolated from clade A HIV-infected
donors. Neutralization testing was performed by Monogram
Biosciences using single round of replication pseudovirus assay
[59]. Numbers indicate antibody IgG concentrations in mg/ml to
reach the IC50 in the neutralization assay. . indicates that the
IC50 for a given virus was not reached at the concentration tested.
ND, not determined. aMLV is the negative control of the assay.
*10-188 and 10-380 are clonally related antibodies.
(PDF)
Table S4 Sequence of YU-2 gp120 overlapping peptides.
(PDF)
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